Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203424 · ClinicalTrials.gov registry record · Phase 2
Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib
A Phase 2 study, sponsored by Translational Oncology Research International.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00203424 is a Phase 2 study that has completed, run by Translational Oncology Research International. The registered enrollment target is 23 participants.
The verdict
NCT00203424, a Phase 2 study, has completed, sponsored by Translational Oncology Research International.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.
Interventions
- DRUG Erlotinib + Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-01 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203424
The ClinicalTrials.gov registry entry for NCT00203424 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Translational Oncology Research International, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erlotinib + Bevacizumab is the first listed.
NCT00203424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203424 about?
NCT00203424 is a clinical study titled "Treatment of Prostate Cancer With Adjuvant Bevacizumab Plus Erlotinib". The purpose of this study is to evaluate the safety and effectiveness of bevacizumab plus erlotinib following radical prostatectomy.
What is the current status of trial NCT00203424?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2006-01. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00203424?
The interventions under investigation include: Erlotinib + Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT00203424?
This trial is sponsored by Translational Oncology Research International, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.